A cannabinoid receptor 1 mutation proximal to the DRY motif results in constitutive activity and reveals intramolecular interactions involved in receptor activation

Brain Research

Volumn 1108, Issue 1, 2006, Pages 1-11

  D'Antona, Aaron M ^a   Ahn, Kwang H ^a   Wang, Lei ^b   Mierke, Dale F ^b   Lucas Lenard, Jean ^a   Kendall, Debra A ^a  

^a UNIVERSITY OF CONNECTICUT   (United States)

^b BROWN UNIVERSITY   (United States)

Author keywords

Cannabinoid; Cannabinoid receptor; CB1; G protein coupled receptor; Ligand binding; Receptor activation

Indexed keywords

4 (1,1 DIMETHYLHEPTYL) 1',2',3',4',5',6' HEXAHYDRO 2,3' DIHYDROXY 6' (3 HYDROXYPROPYL)BIPHENYL; ARGININE; CANNABINOID 1 RECEPTOR; CANNABINOID RECEPTOR; CANNABINOID RECEPTOR AGONIST; CYCLIC AMP; G PROTEIN COUPLED RECEPTOR; GUANINE NUCLEOTIDE BINDING PROTEIN; GUANOSINE 5' O (3 THIOTRIPHOSPHATE); INHIBITORY GUANINE NUCLEOTIDE BINDING PROTEIN; L207A RECEPTOR; LEUCINE; MUTANT PROTEIN; RIMONABANT; UNCLASSIFIED DRUG;

ARTICLE; BINDING AFFINITY; CELL ACTIVITY; CELLULAR DISTRIBUTION; CONTROLLED STUDY; CORRELATION ANALYSIS; GENE MUTATION; HUMAN; HUMAN CELL; LIGAND BINDING; MOLECULAR DYNAMICS; MOLECULAR INTERACTION; PRIORITY JOURNAL; PROTEIN MOTIF;

AMINO ACID MOTIFS; AMINO ACID SEQUENCE; AMINO ACIDS; BINDING, COMPETITIVE; CANNABINOIDS; CELL LINE; CYCLIC AMP; CYCLOHEXANES; CYCLOHEXANOLS; GUANOSINE 5'-O-(3-THIOTRIPHOSPHATE); HUMANS; LIGANDS; MOLECULAR STRUCTURE; MUTATION; PHENOLS; PIPERIDINES; PYRAZOLES; RADIOLIGAND ASSAY; RECEPTOR, CANNABINOID, CB1;

EID: 33747759025     PISSN: 00068993     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.brainres.2006.05.042     Document Type: Article

References (53)

1. Abadji V., Lucas-Lenard J.M., Chin C., and Kendall D.A. Involvement of the carboxyl terminus of the third intracellular loop of the cannabinoid CB1 receptor in constitutive activation of Gs. J. Neurochem. 72 (1999) 2032-2038
2. Baldwin J.M., Schertler G.F.X., and Unger V.M. An alpha-carbon template for the transmembrane helices in the rhodopsin family of G-protein-coupled receptors. J. Mol. Biol. 272 (1997) 144-164
3. Ballesteros J.H., and Weinstein H.W. Integrated methods for the construction of three dimensional models and computational probing of structure-function relations in G-protein coupled receptors. Methods Neurosci. 25 (1995) 366-428
4. Ballesteros J.A., Jensen A.D., Liapakis G., Rasmussen S.G., Shi L., Gether U., and Javitch J.A. Activation of the beta 2-adrenergic receptor involves disruption of an ionic lock between the cytoplasmic ends of transmembrane segments 3 and 6. J. Biol. Chem. 276 (2001) 29171-29177
5. Baranski T.J., Herzmark P., Lichtarge O., Gerber B.O., Trueheart J., Meng E.C., Iiri T., Sheikh S.P., and Bourne H.R. C5a receptor activation. Genetic identification of critical residues in four transmembrane helices. J. Biol. Chem. 274 (1999) 15757-15765
6. Barker E., Westphal R., Schmidt D., and Sanders-Bush E. Constitutively active 5-hydroxytryptamine2C receptors reveal novel inverse agonist activity of receptor ligands. J. Biol. Chem. 269 (1994) 11687-11690
7. Berg K.A., Maayani S., Goldfarb J., Scaramellini C., Leff P., and Clarke W.P. Effector pathway-dependent relative efficacy at serotonin type 2A and 2C receptors: evidence for agonist-directed trafficking of receptor stimulus. Mol. Pharmacol. 54 (1998) 94-104
8. Bouaboula M., Perrachon S., Milligan L., Canat X., Rinaldi-Carmona M., Portier M., Barth F., Calandra B., Pecceu F., Lupker J., Maffrand J.-P., Le Fur G., and Casellas P. A selective inverse agonist for central cannabinoid receptor inhibits mitogen-activated protein kinase activation stimulated by insulin or insulin-like growth factor 1. Evidence for a new model of receptor/ligand interactions. J. Biol. Chem. 272 (1997) 22330-22339
9. Bradford M.M. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal. Biochem. 72 (1976) 248-254
10. Burstein S., Budrow J., Debatis M., Hunter S.A., and Subramanian A. Phospholipase participation in cannabinoid-induced release of free arachidonic acid. Biochem. Pharmacol. 48 (1994) 1253-1264
11. Caramellini C., and Leff P. A three-state receptor model: predictions of multiple agonist pharmacology for the same receptor type. Ann. N. Y. Acad. Sci. 861 (1998) 97-103
12. Cassel D., and Selinger Z. Mechanism of adenylate cyclase activation by cholera toxin: inhibition of GTP hydrolysis at the regulatory site. Proc. Natl. Acad. Sci. U. S. A. 74 (1977) 3307-3311
13. Cheng Y., and Prusoff W.H. Relationship between the inhibition constant (Ki) and the concentration of inhibitor which causes 50 per cent inhibition (i50) of an enzymatic reaction. Biochem. Pharmacol. 22 (1973) 3099-3108
14. Chin C.N., Lucas-Lenard J., Abadji V., and Kendall D.A. Ligand binding and modulation of cyclic amp levels depend on the chemical nature of residue 192 of the human cannabinoid receptor 1. J. Neurochem. 70 (1998) 366-373
15. Chin C.N., Murphy J.W., Huffman J.W., and Kendall D.A. The third transmembrane helix of the cannabinoid receptor plays a role in the selectivity of aminoalkylindoles for CB2, peripheral cannabinoid receptor. J. Pharmacol. Exp. Ther. 291 (1999) 837-844
16. D'Antona A.M., Ahn K.H., and Kendall D.A. Mutations of CB1 t210 produce active and inactive receptor forms: correlations with ligand affinity, receptor stability, and cellular localization. Biochemistry 45 (2006) 5606-5617
17. Ehlert F., and Rathbun B. Signaling through the muscarinic receptor-adenylate cyclase system of the heart is buffered against GTP over a range of concentrations. Mol. Pharmacol. 38 (1990) 148-158
18. Felder C.C., Joyce K.E., Briley E.M., Mansouri J., Mackie K., Blond O., Lai Y., Ma A.L., and Mitchell R.L. Comparison of the pharmacology and signal transduction of the human cannabinoid CB1 and CB2 receptors. Mol. Pharmacol. 48 (1995) 443-450
19. Ge H., Scheinin M., and Kallio J. Constitutive precoupling to G(i) and increased agonist potency in the alpha(2B)-adrenoceptor. Biochem. Biophys. Res. Commun. 306 (2003) 959-965
20. Gerard C.M., Mollereau C., Vassart G., and Parmentier M. Molecular cloning of a human cannabinoid receptor which is also expressed in testis. Biochem. J. 279 Pt. 1 (1991) 129-134
21. Gether U. Uncovering molecular mechanisms involved in activation of G protein-coupled receptors. Endocr. Rev. 21 (2000) 90-113
22. Glass M., and Felder C.C. Concurrent stimulation of cannabinoid CB1 and dopamine D2 receptors augments cAMP accumulation in striatal neurons: evidence for a Gs linkage to the CB1 receptor. J. Neurosci. 17 (1997) 5327-5333
23. Glass M., and Northup J.K. Agonist selective regulation of G proteins by cannabinoid CB1 and CB2 receptors. Mol. Pharmacol. 56 (1999) 1362-1369
24. Gouldson P.R., Kidley N.J., Bywater R.P., Psaroudakis G., Brooks H.D., Diaz C., Shire D., and Reynolds C.A. Toward the active conformations of rhodopsin and the beta2-adrenergic receptor. Proteins 56 (2004) 67-84
25. Greasley P.J., Fanelli F., Rossier O., Abuin L., and Cotecchia S. Mutagenesis and modelling of the alpha 1b-adrenergic receptor highlight the role of the helix 3/helix 6 interface in receptor activation. Mol. Pharmacol. 61 (2002) 1025-1032
26. Horn F., Bettler E., Oliveira L., Campagne F., Cohen F.E., and Vriend G. GPCRDB information system for G protein-coupled receptors. Nucleic Acids Res. 31 (2003) 294-297
27. Houston D.B., and Howlett A.C. Differential receptor-G-protein coupling evoked by dissimilar cannabinoid receptor agonists. Cell Signal 10 (1998) 667-674
28. Howlett A.C. Efficacy in CB1 receptor-mediated signal transduction. Br. J. Pharmacol. 142 (2004) 1209-1218
29. Howlett A.C., and Fleming R.M. Cannabinoid inhibition of adenylate cyclase. Pharmacology of the response in neuroblastoma cell membranes. Mol. Pharmacol. 26 (1984) 532-538
30. Howlett A.C., Barth F., Bonner T.I., Cabral G., Casellas P., Devane W.A., Felder C.C., Herkenham M., Mackie K., Martin B.R., Mechoulam R., and Pertwee R.G. International union of pharmacology. XXVII. Classification of cannabinoid receptors. Pharmacol. Rev. 54 (2002) 161-202
31. Jarrahian A., Watts V.J., and Barker E.L. D2 dopamine receptors modulate Galpha-subunit coupling of the CB1 cannabinoid receptor. J. Pharmacol. Exp. Ther. 308 (2004) 880-886
32. Latronico A.C., Abell A.N., Arnhold I.J., Liu X., Lins T.S., Brito V.N., Billerbeck A.E., Segaloff D.L., and Mendonca B.B. A unique constitutively activating mutation in third transmembrane helix of luteinizing hormone receptor causes sporadic male gonadotropin-independent precocious puberty. J. Clin. Endocrinol. Metab. 83 (1998) 2435-2440
33. Lin S., Khanolkar A.D., Fan P., Goutopoulos A., Qin C., Papahadjis D., and Makriyannis A. Novel analogues of arachidonylethanolamide (anandamide): affinities for the CB1 and CB2 cannabinoid receptors and metabolic stability. J. Med. Chem. 41 (1998) 5353-5361
34. Luo X., Zhang D., and Weinstein H. Ligand-induced domain motion in the activation mechanism of a G-protein-coupled receptor. Protein Eng. 7 (1994) 1441-1448
35. Mackie K., and Hille B. Cannabinoids inhibit N-type calcium channels in neuroblastoma-glioma cells. Proc. Natl. Acad. Sci. U. S. A. 89 (1992) 3825-3829
36. McAllister S.D., Rizvi G., Anavi-Goffer S., Hurst D.P., Barnett-Norris J., Lynch D.L., Reggio P.H., and Abood M.E. An aromatic microdomain at the cannabinoid CB(1) receptor constitutes an agonist/inverse agonist binding region. J. Med. Chem. 46 (2003) 5139-5152
37. McAllister S.D., Hurst D.P., Barnett-Norris J., Lynch D., Reggio P.H., and Abood M.E. Structural mimicry in class A G protein-coupled receptor rotamer toggle switches: the importance of the F3.36(201)/W6.48(357) interaction in cannabinoid CB1 receptor activation. J. Biol. Chem. 279 (2004) 48024-48037
38. Min K.S., Liu X., Fabritz J., Jaquette J., Abell A.N., and Ascoli M. Mutations that induce constitutive activation and mutations that impair signal transduction modulate the basal and/or agonist-stimulated internalization of the lutropin/choriogonadotropin receptor. J. Biol. Chem. 273 (1998) 34911-34919
39. Mukhopadhyay S., and Howlett A.C. Chemically distinct ligands promote differential CB1 cannabinoid receptor-Gi protein interactions. Mol. Pharmacol. 67 (2005) 2016-2024
40. Murphy J.W., and Kendall D.A. Integrity of extracellular loop 1 of the human cannabinoid receptor 1 is critical for high-affinity binding of the ligand CP 55,940 but not SR 141716A. Biochem. Pharmacol. 65 (2003) 1623-1631
41. Okada T., Sugihara M., Bondar A.-N., Elstner M., Entel P., and Buss V. The retinal conformation and its environment in rhodopsin in light of a new 2.2 Å crystal structure. J. Mol. Biol. 342 (2004) 571-583
42. Palczewski K., Kumasaka T., Hori T., Behnke C.A., Motoshima H., Fox B.A., Trong I.L., Teller D.C., Okada T., Stenkamp R.E., Yamamoto M., and Miyano M. Crystal structure of rhodopsin: a G protein-coupled receptor. Science 289 (2000) 739-745
43. Perez D., Hwa J., Gaivin R., Mathur M., Brown F., and Graham R. Constitutive activation of a single effector pathway: evidence for multiple activation states of a G protein-coupled receptor. Mol. Pharmacol. 49 (1996) 112-122
44. Rhee M.-H., Bayewitch M., Avidor-Reiss T., Levy R., and Vogel Z. Cannabinoid receptor activation differentially regulates the various adenylyl cyclase isozymes. J. Neurochem. 71 (1998) 1525-1534
45. Rolz C., and Mierke D.F. Characterization of the molecular motions of constitutively active G protein-coupled receptors for parathyroid hormone. Biophys. Chem. 89 (2001) 119-128
46. Samama P., Cotecchia S., Costa T., and Lefkowitz R.J. A mutation-induced activated state of the beta 2-adrenergic receptor. Extending the ternary complex model. J. Biol. Chem. 268 (1993) 4625-4636
47. Scheer A., Fanelli F., Costa T., De Benedetti P.G., and Cotecchia S. Constitutively active mutants of the alpha 1B-adrenergic receptor: role of highly conserved polar amino acids in receptor activation. EMBO J. 15 (1996) 3566-3578
48. Scheer A., Costa T., Fanelli F., De Benedetti P.G., Mhaouty-Kodja S., Abuin L., Nenniger-Tosato M., and Cotecchia S. Mutational analysis of the highly conserved arginine within the glu/asp-arg-tyr motif of the alpha 1B-adrenergic receptor: effects on receptor isomerization and activation. Mol. Pharmacol. 57 (2000) 219-231
49. Shapiro D.A., Kristiansen K., Weiner D.M., Kroeze W.K., and Roth B.L. Evidence for a model of agonist-induced activation of 5-hydroxytryptamine 2A serotonin receptors that involves the disruption of a strong ionic interaction between helices 3 and 6. J. Biol. Chem. 277 (2002) 11441-11449
50. Wade S.M., Lim W.K., Lan K.-L., Chung D.A., Nanamori M., and Neubig R.R. Gi activator region of alpha 2A-adrenergic receptors: distinct basic residues mediate Gi versus Gs activation. Mol. Pharmacol. 56 (1999) 1005-1013
51. Wilson R.I., and Nicoll R.A. Endocannabinoid signaling in the brain. Science 296 (2002) 678-682
52. Yang Q., and Lanier S.M. Accelerated communication: influence of G protein type on agonist efficacy. Mol. Pharmacol. 56 (1999) 651-656
53. Zuscik M.J., Porter J.E., Gaivin R., and Perez D.M. Identification of a conserved switch residue responsible for selective constitutive activation of the beta 2-adrenergic receptor. J. Biol. Chem. 273 (1998) 3401-3407